Index RUT
P/E 19.75
EPS (ttm) 1.52
Insider Own 0.79%
Shs Outstand 174.58M
Perf Week -0.76%
Market Cap 5.22B
Forward P/E 21.96
EPS next Y 1.37
Insider Trans 2.46%
Shs Float 172.45M
Perf Month -6.25%
Income 272.67M
PEG 1.98
EPS next Q 0.28
Inst Own 98.36%
Short Float 2.50%
Perf Quarter -3.91%
Sales 4.43B
P/S 1.18
EPS this Y -19.96%
Inst Trans 3.09%
Short Ratio 3.25
Perf Half Y 7.06%
Book/sh 8.22
P/B 3.65
EPS next Y 15.39%
ROA 8.55%
Short Interest 4.30M
Perf Year 9.16%
Cash/sh 1.26
P/C 23.77
EPS next 5Y 10.00%
ROE 19.62%
52W Range 24.23 - 35.74
Perf YTD -10.89%
Dividend Est. -
P/FCF 30.55
EPS past 5Y -
ROI 10.59%
52W High -16.00%
Beta 1.33
Dividend TTM -
Quick Ratio 1.39
Sales past 5Y 17.51%
Gross Margin 21.01%
52W Low 23.90%
ATR (14) 0.99
Dividend Ex-Date -
Current Ratio 1.77
EPS Y/Y TTM 74.47%
Oper. Margin 7.15%
RSI (14) 43.21
Volatility 3.13% 3.39%
Employees 5809
Debt/Eq 0.82
Sales Y/Y TTM 9.59%
Profit Margin 6.15%
Recom 1.11
Target Price 39.45
Option/Short Yes / Yes
LT Debt/Eq 0.80
EPS Q/Q 18.83%
Payout 0.00%
Rel Volume 0.82
Prev Close 29.81
Sales Surprise 4.03%
EPS Surprise 15.15%
Sales Q/Q 12.82%
Earnings Apr 23 BMO
Avg Volume 1.32M
Price 30.02
SMA20 -1.70%
SMA50 -5.05%
SMA200 -6.50%
Trades
Volume 1,083,113
Change 0.70%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-27-23 Resumed
Jefferies
Buy
$38
Jul-19-21 Upgrade
Goldman
Neutral → Buy
$20 → $25
Jan-22-21 Initiated
Deutsche Bank
Buy
$22
Jan-11-21 Initiated
JP Morgan
Overweight
$21
Dec-15-20 Initiated
Goldman
Neutral
$18
Jun-24-20 Initiated
BofA/Merrill
Buy
$18
Apr-29-24 04:05PM
Apr-26-24 12:00PM
09:40AM
Apr-25-24 11:27AM
Apr-24-24 03:49AM
(Thomson Reuters StreetEvents)
03:03AM
Loading…
03:03AM
Apr-23-24 11:54AM
08:33AM
08:19AM
08:15AM
07:15AM
(Associated Press Finance)
07:00AM
Apr-22-24 12:10PM
Apr-16-24 10:00AM
Apr-04-24 04:05PM
05:25PM
Loading…
Mar-26-24 05:25PM
Mar-14-24 07:14PM
05:04PM
04:58PM
04:25PM
Mar-07-24 10:07AM
Feb-23-24 12:34PM
Feb-22-24 11:53PM
(Thomson Reuters StreetEvents)
08:20AM
07:31AM
07:24AM
(Associated Press Finance)
07:00AM
Feb-02-24 06:10AM
Jan-22-24 04:05PM
Jan-08-24 07:00AM
05:14AM
Loading…
Dec-19-23 05:14AM
Dec-11-23 04:05PM
Dec-06-23 04:11PM
Nov-07-23 04:05PM
Oct-26-23 09:35AM
Oct-25-23 10:27PM
(Thomson Reuters StreetEvents) -15.49%
07:05PM
09:56AM
08:15AM
07:08AM
(Associated Press Finance)
07:00AM
Oct-20-23 11:47AM
Oct-18-23 12:04PM
Oct-16-23 02:53PM
Oct-02-23 05:56AM
Sep-29-23 03:59PM
08:19AM
Sep-28-23 08:26PM
Sep-27-23 09:24PM
04:05PM
Sep-15-23 09:18AM
Sep-12-23 08:32AM
Sep-08-23 06:23PM
Sep-05-23 07:54AM
Sep-01-23 11:19AM
Aug-31-23 05:00PM
11:40AM
03:34AM
Aug-28-23 09:59AM
Aug-18-23 07:39AM
Aug-14-23 07:03PM
Aug-11-23 09:39AM
Aug-10-23 12:20PM
10:12AM
Aug-03-23 08:06AM
Aug-02-23 07:53AM
07:37AM
Jul-28-23 12:00PM
Jul-27-23 08:25AM
07:20AM
07:00AM
Jul-25-23 05:36AM
Jul-19-23 11:40AM
Jul-06-23 11:22AM
08:00AM
Jun-30-23 01:04PM
Jun-28-23 09:21AM
Jun-27-23 08:18AM
Jun-26-23 01:39PM
(The Wall Street Journal) +5.18%
09:04AM
08:57AM
08:44AM
Jun-21-23 08:00PM
Jun-11-23 03:45AM
Jun-06-23 01:14PM
08:55AM
Jun-05-23 11:40AM
08:31AM
08:25AM
08:13AM
May-23-23 04:05PM
11:53AM
May-18-23 04:05PM
May-05-23 04:05PM
May-04-23 12:29PM
May-03-23 07:35PM
06:27PM
04:53PM
04:31PM
04:30PM
Option Care Health, Inc. engages in the provision of home and alternate site infusion services. The firm provides infusion therapy and other ancillary healthcare services through a national network of full-service pharmacies. The company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients' homes or other nonhospital settings. Its home infusion services consist of anti-infectives, nutrition support, bleeding disorder therapies, immunoglobulin therapy, and other therapies for chronic and acute conditions. The company was founded in 1996 and is headquartered in Bannockburn, IL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Bavaro Michael Chief Human Resources Officer Feb 28 '24 Sale 31.73 1,984 62,944 43,428 Mar 01 04:28 PM KRAEMER HARRY M JANSEN JR Director Feb 26 '24 Buy 31.55 35,000 1,104,352 269,528 Feb 28 04:41 PM RADEMACHER JOHN CHARLES Chief Executive Officer Feb 21 '24 Option Exercise 0.00 11,087 0 705,876 Feb 23 06:21 PM SHAPIRO MICHAEL H. Chief Financial Officer Feb 17 '24 Option Exercise 0.00 3,652 0 180,570 Feb 21 09:55 PM Bierbower Elizabeth D Director Oct 30 '23 Buy 26.37 3,000 79,110 13,515 Nov 01 05:09 PM Pate R Carter Director Aug 17 '23 Buy 34.32 1,465 50,279 106,112 Aug 21 05:08 PM Smyser Collin GC & Corporate Secretary Aug 14 '23 Buy 34.69 2,500 86,725 2,500 Aug 15 05:24 PM KRAEMER HARRY M JANSEN JR Director Aug 11 '23 Buy 34.63 55,000 1,904,518 234,528 Aug 15 05:26 PM Smyser Collin GC & Corporate Secretary May 19 '23 Option Exercise 0.00 812 0 16,623 May 22 04:08 PM
Index RUT
P/E -
EPS (ttm) -1.11
Insider Own 6.92%
Shs Outstand 105.51M
Perf Week 6.92%
Market Cap 182.72M
Forward P/E -
EPS next Y -0.21
Insider Trans 0.05%
Shs Float 100.04M
Perf Month -13.27%
Income -115.15M
PEG -
EPS next Q -0.16
Inst Own 76.77%
Short Float 4.25%
Perf Quarter 40.50%
Sales 516.18M
P/S 0.35
EPS this Y 47.04%
Inst Trans -7.95%
Short Ratio 5.40
Perf Half Y 95.49%
Book/sh 1.09
P/B 1.55
EPS next Y 43.68%
ROA -27.95%
Short Interest 4.25M
Perf Year -36.09%
Cash/sh 0.25
P/C 6.80
EPS next 5Y 15.00%
ROE -78.50%
52W Range 0.55 - 3.78
Perf YTD 65.05%
Dividend Est. -
P/FCF -
EPS past 5Y -17.83%
ROI -45.80%
52W High -55.03%
Beta 2.09
Dividend TTM -
Quick Ratio 0.68
Sales past 5Y 16.25%
Gross Margin 34.38%
52W Low 211.87%
ATR (14) 0.14
Dividend Ex-Date -
Current Ratio 1.28
EPS Y/Y TTM -6.36%
Oper. Margin -19.61%
RSI (14) 55.19
Volatility 7.89% 8.11%
Employees 1700
Debt/Eq 1.33
Sales Y/Y TTM -10.34%
Profit Margin -22.31%
Recom 2.25
Target Price 2.75
Option/Short Yes / Yes
LT Debt/Eq 1.18
EPS Q/Q 76.84%
Payout -
Rel Volume 0.56
Prev Close 1.61
Sales Surprise 0.25%
EPS Surprise 16.20%
Sales Q/Q 0.56%
Earnings May 07 AMC
Avg Volume 787.05K
Price 1.70
SMA20 5.10%
SMA50 1.03%
SMA200 9.57%
Trades
Volume 439,706
Change 5.59%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-13-24 Upgrade
ROTH MKM
Neutral → Buy
$2 → $2.50
Nov-10-22 Upgrade
Craig Hallum
Hold → Buy
$4 → $6
Mar-02-22 Reiterated
UBS
Neutral
$10 → $6.50
Mar-02-22 Reiterated
Truist
Hold
$10 → $5
Mar-02-22 Reiterated
KeyBanc Capital Markets
Overweight
$22 → $16
Mar-02-22 Reiterated
BofA Securities
Underperform
$5.50 → $4.50
Mar-02-22 Reiterated
B. Riley Securities
Neutral
$9 → $6
Mar-02-22 Downgrade
ROTH Capital
Buy → Neutral
$10 → $6
Nov-10-21 Downgrade
UBS
Buy → Neutral
$32 → $15
Nov-10-21 Downgrade
Truist
Buy → Hold
$12
Nov-10-21 Downgrade
Raymond James
Outperform → Mkt Perform
Nov-10-21 Downgrade
B. Riley Securities
Buy → Neutral
$14
Nov-08-21 Downgrade
BofA Securities
Buy → Underperform
$36 → $16
Sep-28-21 Downgrade
Craig Hallum
Buy → Hold
$22
Dec-16-20 Initiated
Truist
Buy
$35
Oct-14-20 Reiterated
B. Riley Securities
Buy
$26 → $33
Oct-13-20 Initiated
UBS
Buy
$35
Oct-06-20 Reiterated
Oppenheimer
Outperform
$25 → $37
Sep-03-20 Resumed
ROTH Capital
Buy
$27
Aug-14-20 Reiterated
B. Riley FBR
Buy
$23 → $26
Show Previous Ratings
Today 03:06AM
May-01-24 06:30AM
Apr-30-24 04:05PM
Apr-24-24 01:12PM
Apr-22-24 02:50AM
08:50AM
Loading…
Apr-11-24 08:50AM
Mar-26-24 08:50AM
Mar-23-24 06:00AM
Mar-14-24 05:32PM
08:19AM
Mar-13-24 04:05PM
07:02AM
(Thomson Reuters StreetEvents)
Mar-12-24 05:34PM
05:15PM
04:22PM
(Associated Press Finance)
04:05PM
Loading…
04:05PM
04:03PM
Feb-27-24 04:05PM
Jan-23-24 04:05PM
Jan-03-24 04:05PM
Dec-04-23 04:05PM
Nov-14-23 12:30PM
Nov-11-23 12:12PM
Nov-10-23 09:43AM
(Thomson Reuters StreetEvents) -31.15%
Nov-09-23 06:26PM
(Associated Press Finance) -10.73%
04:05PM
Nov-07-23 09:07AM
Nov-01-23 08:00AM
Oct-24-23 04:05PM
Sep-27-23 04:05PM
04:05PM
Loading…
Sep-21-23 04:05PM
Sep-05-23 03:30PM
Aug-16-23 08:40AM
Aug-14-23 03:51PM
Aug-10-23 03:27PM
09:13AM
(Thomson Reuters StreetEvents)
Aug-09-23 05:40PM
04:27PM
04:05PM
Aug-04-23 11:44AM
Aug-02-23 04:05PM
Jun-15-23 04:09PM
Jun-12-23 08:00AM
May-15-23 09:00AM
May-11-23 09:03AM
(Thomson Reuters StreetEvents) +19.20%
May-10-23 05:55PM
04:51PM
04:05PM
May-09-23 02:43PM
May-02-23 05:46PM
10:02AM
Apr-21-23 06:35PM
10:39AM
Apr-13-23 04:05PM
Apr-04-23 12:39PM
Mar-28-23 06:46AM
Mar-26-23 07:22AM
Mar-22-23 06:32AM
Mar-20-23 04:10AM
Mar-17-23 08:03AM
(Thomson Reuters StreetEvents) -19.70%
Mar-16-23 05:25PM
04:06PM
04:05PM
Mar-14-23 08:48AM
Mar-10-23 09:35AM
Mar-07-23 04:05PM
12:45PM
Feb-28-23 10:00AM
Feb-23-23 09:35AM
Feb-21-23 01:50PM
Feb-17-23 12:45PM
Feb-14-23 02:30PM
(The Wall Street Journal)
08:30AM
Feb-13-23 05:24PM
08:30AM
Feb-08-23 10:59PM
04:03PM
Feb-02-23 06:59AM
Jan-30-23 12:45PM
08:00AM
Jan-20-23 06:35PM
08:50AM
Jan-19-23 08:15AM
08:00AM
Jan-13-23 05:15PM
Jan-12-23 04:30PM
Jan-04-23 04:15PM
Dec-15-22 10:02AM
Dec-07-22 08:50AM
Nov-14-22 09:55AM
08:50AM
Nov-10-22 08:10AM
Nov-09-22 05:25PM
04:05PM
Nov-03-22 04:05PM
08:00AM
Oct-18-22 04:05PM
Oct-13-22 08:41AM
Sep-26-22 07:45AM
07:30AM
Purple Innovation, Inc. engages in the design and manufacture of comfort technology products. It offers mattresses, bed pillows, seat cushions, mattress protector, and bamboo sheets. The company was founded by Terry V. Pearce and Tony Marion Pearce in 1989 and is headquartered in Lehi, Utah.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Ulrich George Turner Principal Accounting Officer Mar 22 '24 Buy 1.52 4,000 6,061 16,874 Mar 26 08:00 AM DICAMILLO GARY T Director Aug 28 '23 Buy 2.22 10,000 22,182 158,478 Aug 30 11:03 AM McGarvey Casey Kale Chief Legal Officer Jun 02 '23 Buy 2.85 22,300 63,553 108,436 Jun 06 04:10 PM KERBY JEFFERY SCOTT Chief of Owned Retail May 26 '23 Buy 3.45 16,350 56,445 39,427 May 30 05:44 PM DARLING SETH LANE Director May 16 '23 Buy 3.02 17,000 51,425 17,000 May 16 08:35 PM DeMartini Robert CEO May 15 '23 Buy 2.97 50,000 148,665 240,474 May 17 08:02 AM Pate R Carter Director May 15 '23 Buy 2.95 16,949 50,000 16,949 May 15 05:10 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite